Pages that link to "Q57384068"
Jump to navigation
Jump to search
The following pages link to Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled (Q57384068):
Displaying 50 items.
- Aliskiren: the first renin inhibitor for clinical treatment (Q28272666) (← links)
- Sympathetic nervous system overactivity and its role in the development of cardiovascular disease (Q28279754) (← links)
- Na+-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance (Q28394234) (← links)
- Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women (Q30234618) (← links)
- Hypertension with unsatisfactory sleep health (HUSH): study protocol for a randomized controlled trial (Q30252196) (← links)
- Treatment of hypertension in obese patients (Q30429298) (← links)
- Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). (Q33376862) (← links)
- Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure (Q33511929) (← links)
- Severity of obesity and management of hypertension, hypercholesterolaemia and smoking in primary care: population-based cohort study (Q33586657) (← links)
- Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications (Q33609093) (← links)
- Effectiveness of A Four-Week Diet Regimen, Exercise and Psychological Intervention for Weight Loss (Q33666512) (← links)
- Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study (Q33889572) (← links)
- Drug mechanisms to help in managing resistant hypertension in obesity (Q34023578) (← links)
- Resistant hypertension and obstructive sleep apnea: the sparring partners (Q34512680) (← links)
- Pathophysiology of resistant hypertension: the role of sympathetic nervous system (Q34557252) (← links)
- Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. (Q34608252) (← links)
- Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study (Q35005395) (← links)
- Factors that interfere the medication compliance in hypertensive patients. (Q35020135) (← links)
- The pathophysiology of hypertension in patients with obesity (Q35021492) (← links)
- Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups (Q35024225) (← links)
- Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. (Q35032546) (← links)
- Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. (Q35120401) (← links)
- Factors associated with grade 1 hypertension: implications for hypertension care based on the Dietary Approaches to Stop Hypertension (DASH) in primary care settings. (Q35150599) (← links)
- Medical complications of obesity and optimization of the obese patient for colorectal surgery (Q35850150) (← links)
- An observational study of hypertension treatment and patient outcomes in a primary care setting (Q35958431) (← links)
- Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy. (Q35958750) (← links)
- Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study (Q36143544) (← links)
- Management of hypertension in overweight and obese patients: a practical guide for clinicians (Q36255407) (← links)
- Antihypertensive treatment in patients with class 3 obesity (Q36328092) (← links)
- Resistant or difficult-to-treat hypertension (Q36416109) (← links)
- Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation (Q36416167) (← links)
- The first Iranian recommendations on prevention, evaluation and management of high blood pressure (Q36569409) (← links)
- Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index (Q37077205) (← links)
- Management of arterial hypertension in obese patients (Q37119330) (← links)
- Fat intake and cardiovascular response. (Q37119346) (← links)
- Obesity and cognitive dysfunction in heart failure: the role of hypertension, type 2 diabetes, and physical fitness (Q37204307) (← links)
- Management of patients with resistant hypertension: current treatment options (Q37304418) (← links)
- Current pharmacotherapeutic concepts for the treatment of obesity in adults (Q37368688) (← links)
- Management of hypertension in the elderly patient (Q37388460) (← links)
- Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. (Q37523952) (← links)
- Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis (Q37536400) (← links)
- Obesity, hypertension, and chronic kidney disease (Q37601245) (← links)
- Current options for the treatment of resistant hypertension (Q37629838) (← links)
- Aldosterone and arterial hypertension (Q37660912) (← links)
- Unmet needs in managing hypertension: potential role of direct renin inhibition (Q37750291) (← links)
- New class of agents for treatment of hypertension: Focus on direct renin inhibition (Q37801292) (← links)
- Spironolactone Management of Resistant Hypertension (Q37803301) (← links)
- Hypertension treatment update: Focus on direct renin inhibition (Q37868721) (← links)
- A Comparison of the Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination Therapy with Irbesartan Monotherapy in the Treatment of Moderate or Severe Hypertension in Diabetic and Obese Hypertensive Patients: A Post-Hoc Analysis Review (Q37890789) (← links)
- Epidemiology of resistant hypertension (Q37901560) (← links)